KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Deffered Revenue (2019 - 2022)

Esperion Therapeutics filings provide 3 years of Non-Current Deffered Revenue readings, the most recent being $211000.0 for Q2 2022.

  • On a quarterly basis, Non-Current Deffered Revenue fell 80.04% to $211000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $211000.0, a 80.04% decrease, with the full-year FY2021 number at $634000.0, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $211000.0 in Q2 2022 for Esperion Therapeutics, down from $422000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.1 million in Q2 2021 to a low of $211000.0 in Q2 2022.
  • Median Non-Current Deffered Revenue over the past 3 years was $644500.0 (2019), compared with a mean of $637333.3.
  • The widest YoY moves for Non-Current Deffered Revenue: up 80.04% in 2022, down 80.04% in 2022.
  • Esperion Therapeutics' Non-Current Deffered Revenue stood at $655000.0 in 2019, then fell by 3.21% to $634000.0 in 2021, then crashed by 66.72% to $211000.0 in 2022.
  • The last three reported values for Non-Current Deffered Revenue were $211000.0 (Q2 2022), $422000.0 (Q1 2022), and $634000.0 (Q4 2021) per Business Quant data.